Literature DB >> 8027550

Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.

F M Marincola1, P Shamamian, R B Alexander, J R Gnarra, R L Turetskaya, S A Nedospasov, T B Simonis, J K Taubenberger, J Yannelli, A Mixon.   

Abstract

The expression of HLA class I molecules on tumor cells is vital for CD8+T cell recognition of tumor Ags. Loss of HLA class I Ag expression as a result of defective beta 2-microglobulin genes has been described in melanoma cells. To further evaluate mechanisms of tumor escape, HLA class I Ag expression was compared in 24 metastatic melanoma cell lines and 20 melanocyte strains by FACS analysis with use of allele-specific mAbs. Total loss of HLA class I Ag expression was not noted; instead, two relatively common phenomena were identified: 1) A variable degree of expression of HLA-B Ags by melanoma cell lines and melanocytes; however, HLA-A Ags were consistently expressed in all cell types. Furthermore, HLA-B locus Ag expression was detected in vivo in only one of six frozen section specimens obtained from six patients having metastatic melanoma. 2) Loss of allelic expression was noted in two of 14 HLA-A2 (14%) and one of three HLA-A29 (33%) melanoma cell lines and included a full haplotype, which suggests loss of a genomic fragment. Allele-specific PCR amplification demonstrated deletion of genes in linkage disequilibrium within the MHC class II, III, and I regions. Aberrations of HLA class I expression in tumor lines should be considered when assessing MHC-restricted phenomena in in vitro models.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027550

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Authors:  C J Kim; T Prevette; J Cormier; W Overwijk; M Roden; N P Restifo; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  1997-07       Impact factor: 4.456

2.  Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.

Authors:  J N Cormier; M C Panelli; J A Hackett; M P Bettinotti; A Mixon; J Wunderlich; L L Parker; N P Restifo; S Ferrone; F M Marincola
Journal:  Int J Cancer       Date:  1999-03-01       Impact factor: 7.396

Review 3.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

4.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

5.  Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.

Authors:  M Wang; P W Chen; V Bronte; S A Rosenberg; N P Restifo
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-10

6.  NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.

Authors:  Adam W Mailloux; M Rita I Young
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

8.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

9.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Authors:  M J Maeurer; S M Gollin; D Martin; W Swaney; J Bryant; C Castelli; P Robbins; G Parmiani; W J Storkus; M T Lotze
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

10.  Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.

Authors:  Rafael Carretero; José M Romero; Francisco Ruiz-Cabello; Isabel Maleno; Felix Rodriguez; Francisco M Camacho; Luis M Real; Federico Garrido; Teresa Cabrera
Journal:  Immunogenetics       Date:  2008-06-11       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.